Administration of class II HER2-DC1 in combination with anti-PD-1 antibody therapy significantly increased both CD4 and CD8+ T cell infiltration per milligram of tumor (p < 0.01) compared to HER2-DC1 group alone and untreated controls as shown in Figure 7B. Here, CD8A is linked to neoplasm.